Gaedcke and al detected no V600E BRAF mutations in 94 rectal cancer patients suggesting that BRAF mutations [28] and consequently MLH1 gene promoter hypermethylation [15, 17, 18] do not seem to play any role in rectal cancer pathogenesis. This evidence concerns the gene BRAF and rectal cancer.